Fred Alger Management, an investment management company, released its "Alger Weatherbie Specialized Growth Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States and Iran and accelerated investment in artificial intelligence (AI) regained market optimism in the quarter, leading the Information Technology and Industrials sectors upward, and Energy and Utilities lagged because of falling oil and gas prices. In June, the Federal Reserve maintained steady interest rates, but the meeting had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified within sectors adopting the technology. The Weatherbie Specialized Growth Fund's Class A shares outperformed the Russell 2500 Growth Index in the quarter. The Industrials and Information Technology sectors contributed to the relative performance, whereas Financials and Consumer Discretionary sectors detracted. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Alger Weatherbie Specialized Growth Fund highlighted Artivion, Inc. (NYSE:AORT). Artivion, Inc. (NYSE:AORT) is a global manufacturer and distributor of medical devices and implantable human tissues. On July 20, 2026, Artivion, Inc. (NYSE:AORT) closed at $25.37 per share. One-month return of Artivion, Inc. (NYSE:AORT) was 22.68%, and its shares lost 16.55% over the past 52 weeks. Artivion, Inc. (NYSE:AORT) has a market capitalization of $1.23 billion.
Alger Weatherbie Specialized Growth Fund stated the following regarding Artivion, Inc. (NYSE:AORT) in its Q2 2026 investor update:
"Artivion, Inc. (NYSE:AORT) manufactures, processes, and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures, with a focus on treating patients with aortic disease. The company's portfolio includes established products as well as newer technologies designed to improve outcomes in complex cardiovascular procedures. During the quarter, shares detracted from performance after the company reported in-line first-quarter results but modestly lowered its full-year outlook, primarily due to slower-than-expected starter set sales for AMDS, its key new product cycle."
Artivion, Inc. (NYSE:AORT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 28 hedge fund portfolios held Artivion, Inc. (NYSE:AORT) at the end of the first quarter, up from 25 in the previous quarter. Artivion, Inc. (NYSE:AORT) delivered total revenue of $116.3 million in Q1 2026, an increase of 12% on a non-GAAP constant currency basis. While we acknowledge the potential of Artivion, Inc. (NYSE:AORT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Source: Yahoo Finance Top News — This article was automatically imported from the source. Read full article at original source →
